Login / Signup

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.

Laura E BarrettHeather L GardnerLisa G BarberAbbey SadowskiCheryl A London
Published in: BMC veterinary research (2019)
Oclacitinib is well tolerated when given in combination with carboplatin or doxorubicin. Future work is needed to explore whether efficacy is enhanced in this setting.
Keyphrases
  • phase ii study
  • drug delivery
  • cancer therapy
  • phase iii
  • oxidative stress
  • current status
  • clinical trial
  • randomized controlled trial
  • rectal cancer
  • study protocol
  • double blind
  • placebo controlled